Market Cap 22.03M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 167,100
Avg Vol 289,556
Day's Range N/A - N/A
Shares Out 21.60M
Stochastic %K 58%
Beta 1.32
Analysts Strong Sell
Price Target $6.50

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
STRAYNUT
STRAYNUT Feb. 23 at 6:59 PM
$NNVC The invested capital of NanoViricides is 161.6 million, the current market value of Nano is roughly 20.5 million, which is LESS than the appraised value of the lab if sold separately, meaning the entire value of this priceless NV-387 therapeutic technology, 30 years in the making is ZERO. NONSENSE! Let that sink in, I'll wait!
0 · Reply
DavidScott
DavidScott Feb. 23 at 4:28 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $AAL $NNVC $INO $NMAX $ACB
0 · Reply
STRAYNUT
STRAYNUT Feb. 22 at 9:00 PM
$NNVC Below post needs a correction: correction - that are manufactured in their Biosafety Lab-2 (BSL-2) in Shelton, Ct. should be: that are manufactured in their GMP facility at Shelton, CT. Sorry for any confusion!
0 · Reply
STRAYNUT
STRAYNUT Feb. 22 at 8:01 PM
$NNVC The most interesting aspect of the MPOX trial in the Congo is the rapidity with which the results may be publicized. Dr. Diwan has stated that the NV-387 dose will be encapsulated in a "bubble" format that are manufactured in their Biosafety Lab-2 (BSL-2) in Shelton, Ct. and come in a 6-pack. The dosing schedule is to break the plastic wrapper surrounding the dose and place that dose carefully on the tongue of the patient once a day and simply let it melt in the mouth. Two 6-packs worth, (12 doses) is all that should be necessary to eradicate the virus before it can infect the patients cells. Remember, NNVC's nano-polymer, micelle technology (called NV-387) is designed to directly bind and destroy virus particles in the bloodstream, preventing the virus from entering and destroying human cells. Of interest in vizualizing the size of a "nanoviricide", I was told that if you had a teaspoon full of them, there count would be in the billions. AMAZING STUFF !!!
0 · Reply
STRAYNUT
STRAYNUT Feb. 21 at 11:18 PM
$NNVC NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI https://finance.yahoo.com/news/nanoviricides-ceo-discusses-progress-broad-160006955.html
0 · Reply
Staschu
Staschu Feb. 21 at 9:30 AM
$NNVC With the Mpox Orphan Drug Designation application, where do you think the stock price will be if it is all positive?
1 · Reply
STRAYNUT
STRAYNUT Feb. 19 at 12:40 AM
$NNVC Quarterly Report PR https://www.nanoviricides.com/
0 · Reply
STRAYNUT
STRAYNUT Feb. 17 at 11:11 PM
$NNVC NanoViricides, Inc. Common Stock (NNVC) Institutional Holdings NNVC Institutional Holdings Ownership Summary Institutional Ownership 14.09% Total Shares Outstanding (millions) 22 Total Value of Holdings (millions) $3 https://www.nasdaq.com/market-activity/stocks/nnvc/institutional-holdings?page=1&rows_per_page=10
0 · Reply
Love1010
Love1010 Feb. 15 at 9:51 PM
0 · Reply
STRAYNUT
STRAYNUT Feb. 13 at 8:59 AM
$NNVC As an addendum to the below post, NNVC has no debt, so why doesn't a Big Pharma (BP) buy the company when it is so incredibly undervalued? BECAUSE OF A PREFERRED A STOCK OWNED MOSTLY BY DR DIWAN, he has voting control of the company, and therefore no hostile bid from a BG would succeed unless he alone agreed to the offer. When you add to this mix that the company lab is being run successfully WITH ONLY SEVEN EMPLOYEES, you can understand why we are so excited about the Phase II MPOX trial, which will validate the entire NV-387 platform.
1 · Reply
Latest News on NNVC
NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 5 months ago

NanoViricides, Inc. Has Filed its Annual Report


NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 9 months ago

NanoViricides Measles Drug Development Animal Study is Imminent


NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed its Quarterly Report


NanoViricides Engages CRO for Phase II Clinical Trial

Jan 27, 2025, 6:30 AM EST - 1 year ago

NanoViricides Engages CRO for Phase II Clinical Trial


STRAYNUT
STRAYNUT Feb. 23 at 6:59 PM
$NNVC The invested capital of NanoViricides is 161.6 million, the current market value of Nano is roughly 20.5 million, which is LESS than the appraised value of the lab if sold separately, meaning the entire value of this priceless NV-387 therapeutic technology, 30 years in the making is ZERO. NONSENSE! Let that sink in, I'll wait!
0 · Reply
DavidScott
DavidScott Feb. 23 at 4:28 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $AAL $NNVC $INO $NMAX $ACB
0 · Reply
STRAYNUT
STRAYNUT Feb. 22 at 9:00 PM
$NNVC Below post needs a correction: correction - that are manufactured in their Biosafety Lab-2 (BSL-2) in Shelton, Ct. should be: that are manufactured in their GMP facility at Shelton, CT. Sorry for any confusion!
0 · Reply
STRAYNUT
STRAYNUT Feb. 22 at 8:01 PM
$NNVC The most interesting aspect of the MPOX trial in the Congo is the rapidity with which the results may be publicized. Dr. Diwan has stated that the NV-387 dose will be encapsulated in a "bubble" format that are manufactured in their Biosafety Lab-2 (BSL-2) in Shelton, Ct. and come in a 6-pack. The dosing schedule is to break the plastic wrapper surrounding the dose and place that dose carefully on the tongue of the patient once a day and simply let it melt in the mouth. Two 6-packs worth, (12 doses) is all that should be necessary to eradicate the virus before it can infect the patients cells. Remember, NNVC's nano-polymer, micelle technology (called NV-387) is designed to directly bind and destroy virus particles in the bloodstream, preventing the virus from entering and destroying human cells. Of interest in vizualizing the size of a "nanoviricide", I was told that if you had a teaspoon full of them, there count would be in the billions. AMAZING STUFF !!!
0 · Reply
STRAYNUT
STRAYNUT Feb. 21 at 11:18 PM
$NNVC NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI https://finance.yahoo.com/news/nanoviricides-ceo-discusses-progress-broad-160006955.html
0 · Reply
Staschu
Staschu Feb. 21 at 9:30 AM
$NNVC With the Mpox Orphan Drug Designation application, where do you think the stock price will be if it is all positive?
1 · Reply
STRAYNUT
STRAYNUT Feb. 19 at 12:40 AM
$NNVC Quarterly Report PR https://www.nanoviricides.com/
0 · Reply
STRAYNUT
STRAYNUT Feb. 17 at 11:11 PM
$NNVC NanoViricides, Inc. Common Stock (NNVC) Institutional Holdings NNVC Institutional Holdings Ownership Summary Institutional Ownership 14.09% Total Shares Outstanding (millions) 22 Total Value of Holdings (millions) $3 https://www.nasdaq.com/market-activity/stocks/nnvc/institutional-holdings?page=1&rows_per_page=10
0 · Reply
Love1010
Love1010 Feb. 15 at 9:51 PM
0 · Reply
STRAYNUT
STRAYNUT Feb. 13 at 8:59 AM
$NNVC As an addendum to the below post, NNVC has no debt, so why doesn't a Big Pharma (BP) buy the company when it is so incredibly undervalued? BECAUSE OF A PREFERRED A STOCK OWNED MOSTLY BY DR DIWAN, he has voting control of the company, and therefore no hostile bid from a BG would succeed unless he alone agreed to the offer. When you add to this mix that the company lab is being run successfully WITH ONLY SEVEN EMPLOYEES, you can understand why we are so excited about the Phase II MPOX trial, which will validate the entire NV-387 platform.
1 · Reply
STRAYNUT
STRAYNUT Feb. 13 at 12:52 AM
$NNVC The invested capital of NanoViricides is 161.6 million, the current market value of Nano is roughly 20.5 million, which is LESS than the appraised value of the lab if sold separately, meaning the entire value of this priceless NV-387 therapeutic technology, 30 years in the making is ZERO. NONSENSE! Let that sink in, I'll wait!
0 · Reply
STRAYNUT
STRAYNUT Feb. 12 at 8:49 PM
$NNVC MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mpox-orphan-drug-designation-application-filed-for-nv-387-declares-na-1136666
0 · Reply
STRAYNUT
STRAYNUT Feb. 11 at 3:21 PM
$NNVC Short Interest (01/30/26) Shares Sold Short 789,858 Change from Last 20.11% Percent of Float 3.77% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
STRAYNUT
STRAYNUT Feb. 10 at 4:52 PM
$NNVC A Revolutionary Strategy for Viral Infections Emperic Treatment with NV-387 is Possible Stock Symbol: NNVC (NYSE American Just Like Emperic Treatment of Bacterial Infections Became Possible with Penicillin https://www.nanoviricides.com/files/News%20PDFs/Broad-Spectrum%20NV-387%20To%20Enable%20Emperic%20Antiviral%20Treatment%20-%20A%20Revolutionary%20Prospect%20Reminisc.pdf
0 · Reply
drkazmd65
drkazmd65 Feb. 10 at 4:27 PM
$NNVC - Well - it's something: https://www.stocktitan.net/news/NNVC/measles-orphan-drug-designation-application-filed-for-nv-387-maytagfw8zoo.html
0 · Reply
DARKP00L
DARKP00L Feb. 10 at 1:57 PM
$NNVC 08:43 on Feb. 10 2026 NanoViricides Files Application For Orphan Drug Designation For NV-387 To Treat Measles #tradeideas
0 · Reply
Love1010
Love1010 Feb. 5 at 8:58 PM
$NNVC brilliance!
0 · Reply
Vladxccc
Vladxccc Feb. 4 at 5:51 PM
0 · Reply
tomzprofit
tomzprofit Feb. 4 at 7:47 AM
$NNVC CEO Anil Diwan talks about NV-387 being an "Empiric Therapy" like penicillin is now for bacteria infections. The drug has been shown to be effective in 90 to 95 % of all viruses. The global total market for antiviral drugs, not including vaccines is over $50 billion for 2025.
0 · Reply
STRAYNUT
STRAYNUT Feb. 3 at 11:19 PM
$NNVC Feb 02, 8:36 AM NanoViricides announces its NV-387 Phase II Mpox trial in the DRC has received ACOREP regulatory approval and completed the clinical trial application process, with first patient dosing expected to begin once site preparations are finished. FYI
0 · Reply
Love1010
Love1010 Feb. 2 at 8:44 PM
$NNVC massive technical breakdown
0 · Reply
Love1010
Love1010 Feb. 2 at 2:56 PM
$NNVC he's right, know what you own (and don't own)
0 · Reply